Lawsuit Alert: Investors who lost money with shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) should contact the Shareholders Foundation

An investor, who purchased shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT), filed a lawsuit over alleged violations of Federal Securities Laws by Sarepta Therapeutics, Inc. in connection with certain allegedly false and misleading statements.

Investors who purchased shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) have certain options and for certain investors are short and strict deadlines running. Deadline: August 25, 2025. NASDAQ: SRPT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Cambridge, MA based Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. Sarepta Therapeutics, Inc. was engaged in the development of ELEVIDYS, a gene therapy intended to treat patients with Duchenne muscular dystrophy.

On March 18, 2025, Sarepta Therapeutics, Inc. issued a safety update on ELEVIDYS announcing that a patient had died following treatment with ELEVIDYS.

Next, on April 4, 2025, Sarepta Therapeutics, Inc. disclosed that European Union member country authorities had requested that the independent data monitoring committee meet to review death announced on March 18, 2025. Sarepta simultaneously halted recruitment and dosing in some of the ELEVIDYS clinical studies.

Then, on June 15, 2025, Sarepta Therapeutics, Inc. disclosed a second patient had died of acute liver failure following treatment with ELEVIDYS. The Company announced it was suspending shipments of ELEVIDYS for non-ambulatory patients while Sarepta took time to evaluate trial regimens and discussed findings with regulatory authorities. Sarepta also revealed that it was pausing dosing in one of its ELEVIDYS clinical studies.

Finally, on June 24, 2025, the United States Food and Drug Administration ("FDA") issued a Safety Communication announcing it had received reports of two deaths and was investigating the risk of acute liver failure with serious outcomes following treatment with ELEVIDYS.

Shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) declined from $173.25 per share on June 21, 2024, to $16.88 per share on July 01, 2025.

The plaintiff claims that between June 22, 2023, and June 24, 2025, the Defendants made false and/or misleading statements and/or failed to disclose that ELEVIDYS posed significant safety risks to patients, that ELEVIDYS trial regimes and protocols failed to detect severe side effects, that the severity of adverse events from ELEVIDYS treatment would cause the Company to halt recruitment and dosing in ELEVIDYS trials, attract regulatory scrutiny, and create greater risk around the therapy's present and expanded approvals, and that as a result of the foregoing, Defendants materially misled with, and/or lacked a reasonable basis for, their positive statements.

Those who purchased shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.